HRS 2018: Optimizer Cardiac Contractility Device Helps Subset Of Heart-Failure Patients

17 May 2018

The FIX-HF-5C trial, a subgroup study derived from the FIX-HF-5 pivotal trial, shows that the Impulse Dynamics Optimizer cardiac contractility modulation device significantly improved exercise tolerance and quality of life in certain heart-failure patients. Results of the trial were presented at the Heart Rhythm Society conference in Boston. Impulse Dynamics expects to file the final PMA module for US FDA for Optimizer in June.

View of the Boston Harbor in Boston, Massachusetts, USA with its mix of modern and historic architecture in a cross processed image.

Results of the FIX-HF-5C study confirming the benefits of Impulse Dynamics NV's Optimizer cardiac contractility modulation (CCM) device on endpoints that are important to heart-failure patients, including exercise capacity and quality of life, while also demonstrating the system's potential to reduce heart-failure morbidity and mortality, according to principal investigator William Abraham of Ohio State University in Columbus, Ohio (US).

Specifically, 12- and 24-week follow-up data from FIX-HF-5C showed that Optimizer significantly improved exercise tolerance and quality of life in...